OTSKY Overview
Upcoming Projects (OTSKY)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (OTSKY)
-
A Third Opinion: Taking a closer look at Medtronic and Otsuka Recor renal denervation systems
Tickers: MDT, OTSKY
Executed On: Nov 22, 2024 at 05:30 PM EST -
A Second Opinion: Taking a closer look at Medtronic and Otsuka Recor renal denervation systems
Tickers: MDT, OTSKY
Executed On: Nov 21, 2024 at 06:00 PM EST -
Third View: Discussing Otsuka's Phase 3 results of Sibeprenlimab, an anti-APRIL monoclonal antibody that limits Gd-IgA1 production and immune complex formation, for the treatment of IgAN in adults.
Ticker: OTSKY
Executed On: Nov 21, 2024 at 04:30 PM EST -
Second View: Discussing Otsuka's Phase 3 results of Sibeprenlimab, an anti-APRIL monoclonal antibody that limits Gd-IgA1 production and immune complex formation, for the treatment of IgAN in adults.
Ticker: OTSKY
Executed On: Nov 20, 2024 at 02:00 PM EST -
Taking a closer look at Medtronic and Otsuka Recor renal denervation systems
Tickers: MDT, OTSKY
Executed On: Nov 20, 2024 at 10:00 AM EST -
Discussing Otsuka's Phase 3 results of Sibeprenlimab, an anti-APRIL monoclonal antibody that limits Gd-IgA1 production and immune complex formation, for the treatment of IgAN in adults.
Ticker: OTSKY
Executed On: Oct 30, 2024 at 08:30 AM EDT -
A Third Look: Discussing the potential of Rejoyn, the first prescription digital therapeutic authorized for the adjunctive treatment of MDD symptom, with a psychiatrist.
Tickers: OTSKY, Click Therapeutics
Executed On: Apr 23, 2024 at 05:00 PM EDT -
A Second Look: Discussing the potential of Rejoyn, the first prescription digital therapeutic authorized for the adjunctive treatment of MDD symptom, with a psychiatrist.
Tickers: OTSKY, Click Therapeutics
Executed On: Apr 16, 2024 at 02:00 PM EDT -
Discussing the potential of Rejoyn, the first prescription digital therapeutic authorized for the adjunctive treatment of MDD symptom, with a psychiatrist.
Tickers: OTSKY, Click Therapeutics
Executed On: Apr 16, 2024 at 01:00 PM EDT -
A Third Look: Discussing the results published by JAMA Neurology on the Positive Phase 3 Study of REXULTI® (brexpiprazole) for agitation associated with Dementia due to Alzheimer’s Disease
Ticker: OTSKY
Executed On: Mar 27, 2024 at 01:30 PM EDT -
A Third Look: Discussing the results of the ASCERTAIN-TRD comparative effectiveness research trial for ABILIFY (aripiprazole) in patients with treatment resistant depression
Ticker: OTSKY
Executed On: Mar 27, 2024 at 12:45 PM EDT -
A Second Look: Discussing the results of the ASCERTAIN-TRD comparative effectiveness research trial for ABILIFY (aripiprazole) in patients with treatment resistant depression
Ticker: OTSKY
Executed On: Mar 27, 2024 at 11:00 AM EDT -
Discussing the results of the ASCERTAIN-TRD comparative effectiveness research trial for ABILIFY (aripiprazole) in patients with treatment resistant depression
Ticker: OTSKY
Executed On: Mar 25, 2024 at 06:30 PM EDT -
A Second Look: Discussing the results published by JAMA Neurology on the Positive Phase 3 Study of REXULTI® (brexpiprazole) for agitation associated with Dementia due to Alzheimer’s Disease
Ticker: OTSKY
Executed On: Feb 09, 2024 at 01:00 PM EST -
Discussing the results published by JAMA Neurology on the Positive Phase 3 Study of REXULTI® (brexpiprazole) for agitation associated with Dementia due to Alzheimer’s Disease
Ticker: OTSKY
Executed On: Feb 08, 2024 at 06:00 PM EST -
A Third Look: Discussing the potential of Centanafadine, a medication currently in development by Otsuka that for the treatment of ADHD
Ticker: OTSKY
Executed On: Nov 16, 2023 at 10:30 AM EST -
Discussing the potential of Centanafadine, a medication currently in development by Otsuka that has recently succeeded in registrational trials with children and teens for the treatment of ADHD
Ticker: OTSKY
Executed On: Nov 07, 2023 at 11:30 AM EST -
Discussing the potential of Lytgobi(futibatinib) in iCCA and the results from the primary analysis of the global Phase 2 FOENIX*-CCA2 trial in light of the recent accelerated FDA approval
Tickers: OTSKY, Taiho Pharmaceutical
Executed On: Dec 06, 2022 at 10:00 AM EST
Upcoming & Overdue Catalysts (OTSKY)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (OTSKY)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
